⏳ Fetching live dividend data...
Home › Calculator › MPSYF Dividend Calculator 2026
MorphoSys AG · OTC
Price: $73.27 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in MPSYF → $10.52M in 10 years · $23.37/month
MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also boasts a robust pipeline, with several promising candidates under development. These include Pelabresib, a small molecule currently in Phase II clinical trials for myelofibrosis, and Felzartamab, a CD38-targeting antibody undergoing Phase I/II investigation for anti-PLA2R-positive membranous nephropathy, an autoimmune kidney disorder. Additionally, MorphoSys is developing CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. Beyond its proprietary projects, MorphoSys collaborates with pharmaceutical partners on other therapeutic programs. These include Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, psoriatic arthritis, and palmoplantar pustulosis, and MOR210/TJ210 targeting immuno-oncology and autoimmune conditions. The company has forged several strategic alliances to further its mission. Notable partnerships include a regional licensing agreement with I-Mab Biopharma for the development and commercialization of felzartamab across China, Taiwan, Hong Kong, and Macau, as well as a strategic alliance with LEO Pharma. Furthermore, MorphoSys has a joint collaboration and licensing pact with Incyte Corporation for the development and market introduction of tafasitamab. It also participates in a clinical collaboration with Incyte Corporation and Xencor, Inc. to evaluate a combination therapy of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1992, MorphoSys AG maintains its headquarters in Planegg, Germany.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MPSYF position with:
Real after-tax yield depends on where you live and how you hold MPSYF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.73% | -0.07% | $273 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.32% | -0.48% | $232 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.18% | -0.62% | $218 / yr |
| 🇬🇧 UK ISA | 0% | 2.73% | -0.07% | $273 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.49% | -0.31% | $249 / yr |
| 🇨🇦 TFSA | 0% | 2.73% | -0.07% | $273 / yr |
| 🇨🇦 CA Taxable | 25% | 2.05% | -0.75% | $205 / yr |
| 🇦🇺 Super (pension) | 15% | 2.32% | -0.48% | $232 / yr |
| 🇦🇺 AU Taxable | 30% | 1.91% | -0.89% | $191 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.01% | -0.79% | $201 / yr |
| 🇫🇷 FR Taxable | 30% | 1.91% | -0.89% | $191 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
MPSYF pays quarterly — 4 times per year. Next ex-div: TBD.
How MPSYF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MPSYF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MPSYF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
MorphoSys AG (MPSYF) is currently trading at $73.27, 26% below its 52-week high. The current dividend yield is 2.73% based on an annual payout of $2.00 per share.
MorphoSys AG (MPSYF) is a healthcare stock currently trading at $73.27 with a dividend yield of 2.73%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever